Lipodystrophy News and Research

RSS

Tresiba and Ryzodeg approved to improve blood sugar control in adults with diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus.

9 Oct 2015

Lund University researchers discovered 'main switch' that regulates cell invaginations

Lack of microinvaginations in the cell membrane, caveolae, can cause serious diseases such as lipodystrophy and muscular dystrophy. Researchers at Lund University in Sweden have now discovered a "main switch" that regulates the formation of these invaginations.

7 Aug 2015

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards.

24 Jul 2015

Genetic mutation associated with severe loss of body fat, appearance of premature aging in children identified

Researchers at the Translational Genomics Research Institute have identified a genetic mutation associated with the appearance of premature aging and severe loss of body fat in children.

17 Jul 2015

Researchers review ten years of scientific studies on mitochondrial toxicity in pregnant women

Researchers from the Hospital Clinic of Barcelona (Spain) have reviewed ten years' worth of scientific studies on mitochondrial toxicity in pregnant women. Exposure to toxic agents such as viruses, certain drugs, pesticides, alcohol and tobacco cause mitochondrial diseases about which very little is known, and which are transmitted from the mother to the foetus.

20 Feb 2015

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

25 Jul 2014

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients.

21 Jul 2014

Study reveals mechanism underlying abnormal fat accumulation in HIV patients

Building upon their earlier research on the biology of fat metabolism, Joslin scientists discovered that microRNAs -small RNA molecules that play important roles in regulation in many types of tissue - play a major role in the distribution and determination of fat cells and whole body metabolism.

3 Jul 2014

State highlights: Fla. employees' unequal premiums; abuse by Calif. doctor alleged

The Florida Cabinet, state agency managers and legislative staff are among 30,000 top-ranked state workers who will continue to pay ultra-low health insurance premiums in the coming year. In a reverse of the Robin Hood principle, the state charges lower-paid workers six times more than those who have the highest earnings pay. ... [B]oth the House and Senate this week released initial budgets that would keep premiums at the same rate (3/22).

25 Mar 2014

Researchers discover potential new therapeutic target for controlling high blood sugar

A UT Southwestern Medical Center study has identified a new potential therapeutic target for controlling high blood sugar, a finding that could help the estimated 25 million Americans with type 2 diabetes.

19 Mar 2014

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb Company today reported results for the fourth quarter and full year of 2013. The fourth quarter was highlighted by the company's announcement to sell its diabetes business as part of the continued evolution of its successful BioPharma strategy to a specialty care model. The company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Europe and Farxiga in the U.S. In addition, the company provided financial guidance for 2014.

24 Jan 2014

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD).

12 Dec 2013

Aileron Therapeutics concludes first-in-human study of ALRN-5281 Stapled Peptide drug

Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.

7 May 2013

Novel modification of structural protein implicated

Studying a protein that gives structure to the nucleus of cells, Johns Hopkins researchers stumbled upon mutations associated with familial partial lipodystrophy, a rare disease that disrupts normal patterns of fat distribution throughout the body.

21 Mar 2013

Bristol-Myers Squibb to acquire Amylin

Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc. announced today that Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

2 Jul 2012

ASCs promising source of cells for use in plastic surgery and regenerative medicine

Adipose stem cells (ASCs)—stem cells derived from fat—are a promising source of cells for use in plastic surgery and regenerative medicine, according to a special review in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

30 May 2012

New method to easily identify cause of rare diseases

Sanford Health Children's Research Center researcher, Kyle Roux, PhD, has revealed a new method of research that will allow the cause of disease—particularly rare diseases—to become more easily identified.

23 Mar 2012

Amylin outlines key strategic priorities for 2012

Amylin Pharmaceuticals, Inc. today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise.

10 Jan 2012

Scientists identify genetic mutation that causes rare childhood disease

An international collaboration of scientists, including researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health, has identified a genetic mutation that causes a rare childhood disease characterized predominantly by inflammation and fat loss.

1 Nov 2011

Boosted REYATAZ shows durable viral suppression in women with HIV

Bristol-Myers Squibb Company announced results from a long-term, retrospective, European cohort study, which included 1,294 antiretroviral (ARV)-experienced patients from Germany, France and Sweden, that were presented today at the Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

21 Jul 2011